A novel histidine-acetate buffer for freeze-dried monoclonal antibody formulations
European Journal of Pharmaceutics and Biopharmaceutics · 2026
DOI: 10.1016/j.ejpb.2025.114940 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Jia-Yi Lv und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China; …. Hauptthemen laut MEDLINE: Histidine, Antibodies, Monoclonal, Acetates. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Jinhua City Science and Technology Bureau, Science and Technology Plan Project of Taizhou, Zhejiang Province Natural Science Foundation.
Abstract (Originalsprache)
Histidine (His)-hydrochloride (HCl) is widely used in freeze-dried monoclonal antibody (mAb) formulations, but alternative buffers are required when chloride ions are undesirable. This study evaluates His-acetate (Ac) as a substitute and its impact on the stability of two model mAbs with distinct physicochemical properties- infliximab (mAb-1) and a humanized anti-ricin mAb (mAb-2). pH shifts during freeze-drying were compared among His-Ac, His-HCl, and sodium Ac buffers, confirming strong buffering capacity of His-Ac within pH 5.5-6.5. Conformational and colloidal stability assessments revealed that both mAbs displayed higher melting temperatures or favorable diffusion interaction parameters in His-Ac formulations. Moreover, mAb-2 exhibited a higher collapse temperature in His-Ac compared to His-HCl, indicating improved structural integrity or drying efficiency during primary drying. No significant differences were observed in aggregation onset temperature and glass transition temperature. Aggregation and chemical stability under stress conditions were evaluated by micro-flow imaging, size exclusion chromatography, and ion exchange chromatography. No notable changes in subvisible particle counts or monomer content occurred after freeze-drying. Overall, His-Ac demonstrated stability comparable to or better than His-HCl, supporting its use in freeze-dried mAb formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China; Taizhou Institute of Zhejiang University, Taizhou, Zhejiang 317000, Ch…
- Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
- School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
- State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Förderung
- Jinhua City Science and Technology Bureau
- Science and Technology Plan Project of Taizhou
- Zhejiang Province Natural Science Foundation
- Zhejiang University
Zitieren
APA
Lv, J. Y., Gao, H., Xie, H. F., Jin, M. J., Di, B., Xu, J., & Fang, W. J. (2026). A novel histidine-acetate buffer for freeze-dried monoclonal antibody formulations. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2025.114940
Vancouver
Lv JY, Gao H, Xie HF, Jin MJ, Di B, Xu J, et al. A novel histidine-acetate buffer for freeze-dried monoclonal antibody formulations. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2025.114940
BibTeX
@article{Lv2026,
author = {Lv, Jia-Yi and Gao, Han and Xie, Huan-Fang and Jin, Meng-Jia and Di, Bin and Xu, Jin and Fang, Wei-Jie},
title = {A novel histidine-acetate buffer for freeze-dried monoclonal antibody formulations},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
doi = {10.1016/j.ejpb.2025.114940}
}
EUVIMED